Form 6-K NEOVASC INC For: May 03

 

Securities and Exchange Commission

washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

 

For the month of	May		2019
Commission File Number	001-36458
Neovasc Inc.
(Translation of registrant’s name into English)
Suite 5138 - 13562 Maycrest Way Richmond, British Columbia, Canada, V6V 2J7
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

☒

Form 40-F

☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):          

 

            Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):           

 

 

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

 

Document
Document 1		News Release dated May 3, 2019 - Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

 

DOCUMENT 1

 

 

 

Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

Conference Call Scheduled for 4:30 pm Eastern Time on May 9^th 

NASDAQ, TSX: NVCN

VANCOUVER, May 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended March 31, 2019 and host a conference call and webcast at 4:30 pm Eastern Time on Thursday, May 9, 2019.

 

Conference Call & Webcast Thursday, May 9th @ 4:30 pm Eastern Time
Domestic:	877-407-9208
International:	201-493-6784
Passcode:	13689510
Webcast:	http://public.viavid.com/index.php?id=133943

 

A replay of the event will be available via webcast through August 9^st on the Company's website, www.neovasc.com, or at http://public.viavid.com/index.php?id=133943.

About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.

 

View original content:http://www.prnewswire.com/news-releases/neovasc-to-announce-first-quarter-2019-financial-results-on-thursday-may-9th-300843366.html

SOURCE Neovasc Inc.

View original content: http://www.newswire.ca/en/releases/archive/May2019/03/c4573.html

%CIK: 0001399708

For further information: Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, [email protected]; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568

CO: Neovasc Inc.

CNW 07:30e 03-MAY-19

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

				Neovasc Inc.
				(Registrant)
Date:		May 3, 2019		By:	/s/ Chris Clark
					Name: Chris Clark Title: Chief Financial Officer

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Volato Announces Changes to Board Composition
• Using AI to Improve Diagnosis of Rare Genetic Disorders
• New Premium Merino Wool Thermal Collection to Be Launched by Thermajohn and Thermajane